(Circulation. 1996;93:1946-1950.)
© 1996 American Heart Association, Inc.
Articles |
New Insights Into the Cardiac Natriuretic Peptides
From the Division of Cardiology, Northwestern University Medical School, Chicago, Ill.
Correspondence to Robert O. Bonow, MD, Division of Cardiology, Northwestern University Medical School, 250 E Superior St, Suite 524, Chicago, IL 60611.
Key Words: Editorials • peptides • natriuretic peptides • heart failure
 |
Introduction |
|---|
Cardiac natriuretic peptides contribute importantly to the maintenance of sodium and volume homeostasis in health and disease. The hemodynamic, renal, and endocrinologic effects of these peptides have been the subject of intense basic and clinical investigation for more than 15 years. In particular, the activation of the cardiac natriuretic peptide system in patients with LV dysfunction has generated considerable interest recently, because elevated circulating levels of these substances have important prognostic and therapeutic implications. Unlike the vasoconstrictor neurohormones that are also activated in the setting of LV dysfunction, such as norepinephrine, the renin-angiotensin system, and arginine vasopressin, which play a pathogenetic role in the progression of ventricular dysfunction and development of heart failure, the cardiac natriuretic peptides have beneficial, compensatory actions to promote systemic arterial dilation, natriuresis, diuresis, and renin inhibition.
ANP is a 28–amino acid peptide synthesized and secreted by the atria.1 2 3 ANP is stored in the myocyte as a 126–amino acid prohormone. On secretion, the prohormone is split into an N-terminal moiety of 98 amino acids (N-ANP) and the biologically active ANP in equimolar amounts.3 N-ANP is more easily measured; it has a significantly longer half-life in plasma compared with ANP, which is very short lived (half-life, 2.5 minutes2 ) and thus has up to 50 times the plasma concentration of ANP.2 3 4 In addition, N-ANP is more stable under laboratory conditions for measurement.5
It is now well established that circulating ANP levels are increased in
patients with chronic congestive heart failure in proportion to the
severity of the
This article has been cited by other articles:
 |
|
 |
|
  G. Mercuro, C. Cadeddu, A. Piras, M. Dessi, C. Madeddu, M. Deidda, R. Serpe, E. Massa, and G. Mantovani Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, September 1, 2007; 12(9): 1124 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Qian, A. Leung, P. Harding, and M. C. LaPointe PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1740 - H1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lev-Sagie, B. Bar-Oz, L. Salpeter, D. Hochner-Celnikier, I. Arad, and A. Nir Plasma Concentrations of N-Terminal Pro-B-Type Natriuretic Peptide in Pregnant Women near Labor and during Early Puerperium Clin. Chem., October 1, 2005; 51(10): 1909 - 1910. [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Sun, C. Dominguez, N. A. Mallavaram, and J. M. Quaegebeur Dysfunction of atrial and B-type natriuretic peptides in congenital univentricular defects J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1104 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vanderheyden, M. Goethals, S. Verstreken, B. De Bruyne, K. Muller, E. Van Schuerbeeck, and J. Bartunek Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suzuki, M. Yoshimura, M. Nakayama, Y. Mizuno, E. Harada, T. Ito, S. Nakamura, K. Abe, M. Yamamuro, T. Sakamoto, et al. Plasma Level of B-Type Natriuretic Peptide as a Prognostic Marker After Acute Myocardial Infarction: A Long-Term Follow-Up Analysis Circulation, September 14, 2004; 110(11): 1387 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jernberg, M. Stridsberg, P. Venge, and B. Lindahl N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation J. Am. Coll. Cardiol., August 7, 2002; 40(3): 437 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suzuki, T. Yamazaki, and Y. Yazaki The role of the natriuretic peptides in the cardiovascular system Cardiovasc Res, August 15, 2001; 51(3): 489 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. He, D. Wang, X.-P. Yang, O. A. Carretero, and M. C. LaPointe Inducible regulation of human brain natriuretic peptide promoter in transgenic mice Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H368 - H376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Iivainen, K. W.E. Groundstroem, J. T. Lahtela, T. J. Talvensaari, A. Pasternack, and A. Uusitalo Serum N-terminal atrial natriuretic peptide in adult patients late after surgical repair of atrial septal defect Eur J Heart Fail, June 1, 2000; 2(2): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kataoka and S. Takada The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Langenickel, I. Pagel, K. Hohnel, R. Dietz, and R. Willenbrock Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1500 - H1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. WILLENBROCK, I. PAGEL, M. SCHEUERMANN, K. HÖHNEL, H. S. MACKENZIE, B. M. BRENNER, and R. DIETZ Renal Function in High-Output Heart Failure in Rats: Role ofEndogenous Natriuretic Peptides J. Am. Soc. Nephrol., March 1, 1999; 10(3): 572 - 580. [Abstract] [Full Text]
|
|
|
|
|
|
M. L Kuroski de Bold Estrogen, natriuretic peptides and the renin-angiotensin system Cardiovasc Res, March 1, 1999; 41(3): 524 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Richards, M G Nicholls, T G Yandle, H Ikram, E A Espiner, J G Turner, R C Buttimore, J G Lainchbury, J M Elliott, C Frampton, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction Heart, February 1, 1999; 81(2): 114 - 120. [Abstract] [Full Text]
|
|
|
|
|
|
K.-B. Kim, C.-H. Lee, C.-H. Kim, Y.-J. Cha, S. :, and J. L. Cox Effect of the Cox maze procedure on the secretion of atrial natriuretic peptide J. Thorac. Cardiovasc. Surg., January 1, 1998; 115(1): 139 - 147. [Abstract] [Full Text] [PDF]
|
|